Stamford Therapeutics Consortium

Interstitial Cystitis / Painful Bladder Syndrome

Stamford Therapeutics Consortium is currently conducting a Phase II study on interstitial cystitis/ painful bladder syndrome (IC/PBS) sponsored by Pfizer.

Summary: The purpose of the study is to test the efficacy and safety of several dose levels of tanezumab for reducing pain with sufficient tolerability.

www.bladderpainstudy.com

For More Information Please Contact:
Judy Dalgin (Site Manager)
email: jdalgin@stctrials.com
telephone: 203-325-8529


Eligibility:


• Ages Eligible for Study: 18 Years to 75 years

• Genders Eligible for Study: Both

• Accepts Healthy Volunteers: No


Partial Inclusion Criteria:


• Patients with interstitial cystitis/ painful bladder syndrome for more than 6 months with moderate to severe pain and a micturition frequency greater than 7 per day.

• Patients who have been on stable oral medicines for interstitial cystitis/ painful bladder syndrome for at least 3 months. Other therapies might need to be stopped.


Partial Exclusion Criteria:

• Patients on certain recent treatments for interstitial cystitis/ painful bladder syndrome.

• Body mass index (BMI) of >39 kg/m2.

• History of allergic or anaphylactic reaction to a therapeutic or diagnostic monoclonal antibody or IgG-fusion protein.

• Patients with peripheral neuropathy.

• Patients with Type I or type II diabetes mellitus who have an HbA1c > 8.0%.

Stamford Therapeutics Consortium

Website Designed And Maintained By Skye Communication, LLC.